Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.87M$3.87Mderived−10.2% vs Q4 2024 Net Income-$16.52M-$16.52MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$11,453,000N/M Operating Cash Flowderived-$9,833,000N/M Margins · derivedOperating margin-296.3%+587.7 pt vs Q4 2024
Net margin-427.5%+389.2 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end